Releases New Research Report on Hydroxychloroquine (Plaquenil) Market 2020-2025 | International Company's - Sanofi, Actavis (TEVA ), Mylan, Novartis, Covis Pharma, Apotex, Sun Pharma, Zydus Cadila

Global Hydroxychloroquine (Plaquenil) Market Synopsis:

The exclusive research report on the Global Hydroxychloroquine (Plaquenil) Market 2020-2025 examines the market in detail along with focusing on significant market dynamics for the key players operating in the market. Global Hydroxychloroquine (Plaquenil) Industry research report offers granulated yet in-depth analysis of revenue share, market segments, revenue estimates and various regions across the globe.

According to the market research study, the Hydroxychloroquine (Plaquenil) is racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine (Plaquenil) is an aminoquinoline like chloroquine. Hydroxychloroquine (Plaquenil) is commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine (Plaquenil) is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of quinacrine with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2. It is taken by mouth. Hydroxychloroquine (Plaquenil) is also being used as an experimental treatment for coronavirus disease 2019 (COVID-19).

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/258560 .

Significant points in table of contents: Market Definition, Market Overview, Business Introduction, Segmentation (Region Level), Segmentation (Type Level), Segmentation (Industry Level), Segmentation (Channel Level), Market Forecast Year, Segmentation Type, Segmentation Industry, Market Cost Analysis, and Conclusion. The Hydroxychloroquine (Plaquenil) Market is segmented based on Product, source, application and Regions. On the basis of product, the market is sub-segmented.

Regionally, North America and Europe holds major share in Global Hydroxychloroquine (Plaquenil) Market. Moreover, Asia-Pacific is expected to record higher growth rate in Hydroxychloroquine (Plaquenil) market during the forecast year.

Top Major Key Players in the Global Hydroxychloroquine (Plaquenil) Market:

1 Sanofi

2 Actavis (TEVA )

3 Mylan

4 Novartis

5 Covis Pharmaceutical

6 Cardinal Health

7 Apotex Corporation

8 Hikma Pharmaceuticals

9 Aphena Pharma

10 Concordia Healthcare

11 AvKARE (Amneal Pharmaceuticals)

12 Ipca Laboratories

13 Shanghai Pharmaceuticals Holding

14 Taj Pharmaceuticals

15 Cinkate Corporation

16 Cadila Healthcare

17 Sun Pharma

18 Zydus Cadila

19 Advanz Pharma

20 Bristol Laboratories

21 Hanlim Pharmaceutical

22 Kyung Poong and More...................

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on "Global Hydroxychloroquine (Plaquenil) Market Report 2020" @ https://www.businessindustryreports.com/buy-now/258560/single .

Product Type Segmentation

1 100mg

2 200mg

3 Others

Industry Segmentation

1 Lupus Erythematosus

2 Rheumatoid Arthritis

3 COVID-19

4 Others

Big Medical Industry News:

Sanofi (March 30, 2020) - Sanofi: First patient outside U.S. treated in global Kevzara (sarilumab) clinical trial program for patients with severe COVID-19 - The first patient outside of the U.S. has been treated as part of a global clinical program evaluating Kevzara (sarilumab) in patients hospitalized with severe COVID-19. The global clinical program has now been initiated in Italy, Spain, Germany, France, Canada, Russia and the United States - all countries that have been impacted by COVID-19.

This is the second multi-center, double-blind, Phase 2/3 trial as part of the Kevzara COVID-19 program, and the companies are continuing to work with health authorities around the world to secure initiation at additional sites. This follows Sanofi and Regeneron's announcement earlier this month of the initiation of the first trial, which is U.S.-based.

"Sanofi and Regeneron are relentlessly working to rapidly initiate trials around the world that will help determine whether Kevzara has the potential to play a role in addressing the COVID-19 global health crisis. These trials will provide important data to determine whether Kevzara ameliorates the life-threatening complications of COVID-19 infections by counteracting the overactive inflammatory responses in the lungs when damaged by the virus. In these unprecedented times, we are deeply grateful for the daily collaboration with health authorities that are enabling us to conduct this clinical work so quickly," said John Reed, M.D., Ph.D., Sanofi's Global Head of Research and Development. "In addition to this clinical trial aiming to help critically ill COVID-19 patients, our work continues to bring forth a vaccine for disease prevention, along with efforts to provide other important Sanofi medicines that may help patients impacted by COVID-19."

Kevzara is a fully-human monoclonal antibody that inhibits the interleukin-6 (IL-6) pathway by binding and blocking the IL-6 receptor. IL-6 may play a role in driving the overactive inflammatory response in the lungs of patients who are severely or critically ill with COVID-19 infection. The role of IL-6 is supported by preliminary data from a single-arm study in China using another IL-6 receptor inhibitor.

"Data from a single-arm study in China suggest that the interleukin-6 pathway may play an important role in the overactive inflammatory response in the lungs of patients with COVID-19. Despite this encouraging finding, it's imperative to conduct a properly designed, randomized trial to understand the true impact of Kevzara, which we are now doing through this global clinical trial program," said George D. Yancopoulos, M.D., Ph.D., Co-founder, President and Chief Scientific Officer of Regeneron. "In addition to the Kevzara program, Regeneron continues to rapidly advance a novel antibody cocktail for the prevention and treatment of COVID-19."

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/258560 .

Major Points in Table of Contents:

Global Hydroxychloroquine (Plaquenil) Market Report 2020

1 Hydroxychloroquine (Plaquenil) Product Definition

2 Global Hydroxychloroquine (Plaquenil) Market Manufacturer Share and Market Overview

3 Manufacturer Hydroxychloroquine (Plaquenil) Business Introduction

4 Global Hydroxychloroquine (Plaquenil) Market Segmentation (Region Level)

5 Global Hydroxychloroquine (Plaquenil) Market Segmentation (Product Type Level)

6 Global Hydroxychloroquine (Plaquenil) Market Segmentation (Industry Level)

7 Global Hydroxychloroquine (Plaquenil) Market Segmentation (Channel Level)

8 Hydroxychloroquine (Plaquenil) Market Forecast 2020-2025

9 Hydroxychloroquine (Plaquenil) Segmentation Product Type

10 Hydroxychloroquine (Plaquenil) Segmentation Industry

11 Hydroxychloroquine (Plaquenil) Cost of Production Analysis

12 Conclusion

................... Request free sample to get a complete Table of Content

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined - we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune - India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.